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MYCN is a highly conserved transcription factor with multifaceted roles in development and disease.
Mutations in MYCN are associated with Feingold syndrome, a developmental disorder characterized in
part by congenital heart defects. Mouse models have helped elucidate MYCN functions; however its
cardiac-speciﬁc roles during development remain unclear. We employed a Cre/loxp strategy to uncover
the speciﬁc activities of MYCN in the developing mouse myocardium. Myocardial deletion of Mycn
resulted in a thin-myocardial wall defect with dramatically reduced trabeculation. The mutant heart
defects strongly resemble the phenotype caused by disruption of BMP10 and Neuregulin-1 (NRG1)
signaling pathways, two central mediators of myocardial wall development. Our further examination
showed that expression of MYCN is regulated by both BMP and NRG1 signaling. The thin-wall defect in
mutant hearts is caused by a reduction in both cell proliferation and cell size. MYCN promotes
cardiomyocyte proliferation through regulating expression of cell cycle regulators (including CCND1,
CCND2, and ID2) and promotes cardiomyocyte growth through regulating expression of p70S6K. In
addition, expression of multiple sarcomere proteins is altered in Mycn myocardial-inactivation
embryos, indicating its essential role for proper cardiomyocyte differentiation. In summary, Mycn acts
downstream of BMP and NRG1 cardiogenic signaling pathways to promote normal myocardial wall
morphogenesis.
& 2012 Elsevier Inc. All rights reserved.Introduction
The heart is the ﬁrst organ to develop and function during
embryogenesis. In order to sustain the growing embryo, heart
muscle must rapidly expand through cardiomyocyte proliferation,
growth, and differentiation (Christoffels et al., 2000; Sedmera
et al., 2000). The relatively low-proliferative nonchamber myo-
cardium along the inner curvature of the heart includes the
atrioventricular canal (AVC), the outﬂow tract, and the conduction
system (Christoffels et al., 2004; Evans et al., 2010). Atrial and
ventricular chamber myocardium is characterized by highly
proliferative, less differentiated cardiomyocytes (Christoffels
et al., 2000, 2004; Evans et al., 2010). After rightward looping,
the proliferating cardiomyocytes increase chamber mass and
volume by contributing to the thickening myocardial wall and
to the trabecular myocardium on the luminal side of the ven-
tricles (Christoffels et al., 2000; Dunwoodie, 2007; Sedmera et al.,
2000; Srivastava and Olson, 2000). The trabecular myocardium
consists of organized layers of cardiomyocytes with muscular
projections (Sedmera et al., 2000). It has multiple roles during
early heart development including coordinating intraventricularll rights reserved.conduction, enhancing contractile force to support continuing
embryonic development, and facilitating nutrient/oxygen sup-
plies to the myocardium (Dunwoodie, 2007; Sedmera et al.,
2000). Later in development, the trabecular myocardium is
incorporated into the compact myocardium, papillary muscles,
and the interventricular septum (IVS) (Sedmera et al., 2000).
Abnormalities in ventricular myocardial wall morphogenesis
cause embryonic lethality in mice (Chen et al., 2004; Gassmann
et al., 1995; Lai et al., 2010; Lee et al., 1995; Meyer and
Birchmeier, 1995), and adult cardiomyopathies in humans
(Klaassen et al., 2008; Pignatelli et al., 2003; Weiford et al.,
2004; Xing et al., 2006).
MYCN is a member of the conserved MYC family of transcription
factors involved in development and disease (Adhikary and Eilers,
2005; Brunner andWinter, 1991; Charron et al., 1992; Hurlin, 2005;
Kenney et al., 2003, 2004; Knoepﬂer et al., 2002; Moens et al., 1992;
Moens et al., 1993; Okubo et al., 2005; Ota et al., 2007; Sawai et al.,
1993; Stanton et al., 1992; Strieder and Lutz, 2002; van Bokhoven
et al., 2005). Multiple developmental signaling pathways converge
on MYCN and, depending on the cellular context, MYCN can
promote proliferation and growth, inhibit terminal differentiation,
and regulate apoptosis (Adhikary and Eilers, 2005; Hurlin, 2005;
Kenney et al., 2003, 2004; Knoepﬂer et al., 2002; Okubo et al., 2005;
Ota et al., 2007; Strieder and Lutz, 2002). Haploinsufﬁciency for
MYCN is associated with Feingold syndrome (FS, OMIM 164280),
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defects (CHDs) (Brunner and Winter, 1991; Bu¨ttiker et al., 2000;
Celli et al., 2003; Genevieve et al., 2007; Piersall et al., 2000; van
Bokhoven et al., 2005). In mice, global deletion or severe reduction
of MYCN causes phenotypes that are similar to, but more severe
than those associated with FS (Charron et al., 1992; Moens et al.,
1992, 1993; Sawai et al., 1993; Stanton et al., 1992). Mice null for
Mycn (Charron et al., 1992; Sawai et al., 1993; Stanton et al., 1992)
or compound heterozygous for a null and a hypomorphic Mycn
allele (Moens et al., 1993) (with MYCN protein reduced to 15% of
normal) had heart defects such as delayed development with no
septavalvulogenesis (Charron et al., 1992), lack of IVS formation
(Sawai et al., 1993), and underdeveloped ventricular myocardial
walls (Charron et al., 1992; Moens et al., 1993; Sawai et al., 1993;
Stanton et al., 1992). These studies provided evidence that Mycn
potentially has roles in several key cardiogenic processes, yet it
remains unclear if the reported heart defects were caused by grossly
abnormal embryo development. Moreover, global removal of Mycn
from the developing embryo precludes investigation of its functions
within speciﬁc cardiac tissues during cardiogenesis.
Our lab and others have identiﬁed Mycn as a transcriptional
target of Bone Morphogenetic Protein (BMP) signaling in the
myocardium during heart development (Cai et al., 2005; Song
et al., 2007b). BMP cytokines are necessary for cardiomyocyte
induction, proliferation, and survival during chamber morphogen-
esis (Azhar et al., 2003; Barnett and Desgrosellier, 2003; Chen et al.,
2004; De´lot, 2003; De´lot et al., 2003; Gaussin et al., 2005, 2002; Jiao
et al., 2003; Judge and Dietz, 2005; Loeys et al., 2006; McFadden and
Olson, 2002; Song et al., 2007a; Srivastava, 2003; Waite and Eng,
2003; Zaffran and Frasch, 2002). BMP signaling is also important for
AVC valvuloseptal development (Desgrosellier et al., 2005; Gaussin
et al., 2005, 2002; Jiao et al., 2003; Ma et al., 2005; Moskowitz et al.,
2011; Park et al., 2006; Rivera-Feliciano and Tabin, 2006; Song et al.,
2007a, 2011; Sugi et al., 2004; Wang et al., 2005). In the current
study, we tested the hypothesis that myocardial Mycn encodes an
essential regulator of cardiomyocyte proliferation, size, survival, and
differentiation, using a novel mouse model with Mycn speciﬁcally
removed from the myocardium.Materials and methods
Mice
This study conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication no. 85–23, revised 1996). All protocols
were approved by the Institutional Animal Care and Use Com-
mittee at the University of Alabama at Birmingham. The cTnt-Cre
(Jiao et al., 2003) and Mycnloxp (Knoepﬂer et al., 2002) transgenic
mouse lines have been described previously. Mycnloxp mice
were provided by R. Eisenman, Fred Hutchinson Cancer
Research Center. Male cTnt-Cre;Mycnloxp/þ mice were mated with
Mycnloxp/loxp females to conditionally delete Mycn from the devel-
oping mouse myocardium. Upon cTnt-Cre mediated recombination,
the entire coding region of Mycn is deleted within the myocardium
between embryonic day E9.5 and E10.5. The day of the plug was
considered E0.5. Embryos were dissected in PBS and processed for
further experiments. Living embryos were deﬁned by beating
hearts. Controls in all experiments were cTnt-Cre negative litter-
mates. Only living embryos were used for experiments.
DNA analyses and western blot
Genotyping was performed on tissue from the yolk sac or tail.
Primers and PCR conditions for cTnt-Cre, Mycn and Smad4 weredescribed previously (Jiao et al., 2003; Knoepﬂer et al., 2002; Yang
et al., 2002). The distribution of genotypes of living embryos was
compared with the expected Mendelian ratio and a chi-square
test was performed for statistical analysis, with Po0.05 consid-
ered signiﬁcant. Semiquantitative PCR analysis was performed on
genomic DNA isolated from pooled embryonic heart ventricles
and whole bodies from Mycnloxp/loxp and cTnt-Cre;Mycnloxp/loxp
littermates. Western analysis was performed as described pre-
viously (Song et al., 2007a). Results were analyzed with ImageJ,
public domain NIH Image program (developed at the U.S. National
Institutes of Health and available at http://imagej.nih.gov/ij/).
Experiments of histology, immunohistochemistry,
immunoﬂuorescence, and in situ hybridization
Hematoxylin and Eosin (HE) staining, immunohistochemistry
(IHC), and immunoﬂuorescence (IF) experiments were performed
as described previously (Song et al., 2007a). Slides were counter-
stained with Hematoxylin QS (Vector labs) and DAPI to visualize
total nuclei for IHC and IF analysis, respectively. A light micro-
scope (Zeiss AxioCam MRc) with a Zeiss Axio Imager A1 digital
camera and AxioVision AC software were used for imaging.
Images were processed with Adobe Photoshop. In situ hybridiza-
tion using a Bmp10 probe was performed as described in Chen
et al. (2004).
Embryonic mouse heart cultures
E11.5 ICR hearts were isolated in PBS and placed in 1.5 mL
DMEM (Invitrogen) supplemented with 1% Glutamine and 10%
FBS in a 24-well plate. Embryonic hearts were treated with
BMP10 (100 ng/ml, R&D), BMP inhibitor DMH1 (8 mM, Sigma),
Neuregulin-1 (625 ng/ml, R&D), or ERBB2 inhibitor AG1478
(100 mM, Calbiochem) for 22 h before Western analysis.
Analysis of cardiomyocyte proliferation, apoptosis, and size
Cell proliferation experiments were performed by both
phospho-Histone H3 (pH3) staining and BrdU labeling experi-
ments. For pH3 staining, sagittal sections of parafﬁn-embedded
embryos were stained with an antibody against pH3 (Upstate) to
identify mitotic cells and with DAPI to identify nuclei (Song et al.,
2007a, 2007b). Cells were counted within 4 regions of the heart:
the atrial myocardium, atrioventricular canal myocardium, cush-
ion mesenchyme, and ventricular myocardium. BrdU labeling
experiments were performed as described in (Li and Rozen,
2006). Brieﬂy, pregnant female mice (E10.5) were injected with
BrdU (50 mg/kg, Invitrogen). 1.5 h afterwards, embryos were
isolated and processed for wax embedding. Embryos were sagit-
tally sectioned and stained with an antibody against BrdU (Iowa
Hybridoma Bank). To visualize apoptotic cells, sagittal sections of
parafﬁn-embedded embryos were subjected to terminal
transferase-mediated dUTP-biotin nickend labeling (TUNEL)
experiments with DeadEndTM Fluorometric TUNEL System (Pro-
mega), per the manufacturer’s protocol. Apoptosis was calculated
as the number of positive cells divided by total cell number (Song
et al., 2007a). Cells were counted within 4 regions of the heart:
the atrial myocardium, atrioventricular canal myocardium, cush-
ion mesenchymal cells, and ventricular myocardium. For both
proliferation and apoptosis experiments, 3 embryos of each
genotype were analyzed from three different litters, and at least
three sections were analyzed for each embryo. A two-tailed,
unpaired student’s t test was used to calculate P values, with
Po0.05 considered signiﬁcant.
Cardiomyocyte width was measured as previously described
(Wang et al., 2010). Brieﬂy, immunostaining experiments were
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Agglutinin Conjugate (conjugated with Oregon Green 488, Invi-
trogen) to outline cell membranes, an antibody against TNNT2 to
distinguish cardiomyocytes, and DAPI mounting media (Vecta-
shield) to identify nuclei. Samples were examined with a Leica
SP1 confocal microscope. Images from comparable regions of the
ventricle wall were analyzed for each embryo. To measure
cardiomyocyte width, we identiﬁed cross sections of cardiomyo-
cytes that cut through the nuclei and measured width as the
shortest axis through the middle of the nucleus. Three embryos
were analyzed for each genotype. A two-tailed, unpaired Student’s
t test was used to calculate P values, with Po0.05 considered
signiﬁcant. Results are expressed as mean þ/standard error.
Antibodies and reagents
Antibodies for MYCN (ab16898, Western blotting (WB)), a-
MHC (ab50967, WB 1:1000), b-MHC (ab11083, WB, 1:75,000),
MLC1V (ab680, WB, 1:20,000), and TNNI3 (ab19615, WB, 1:2000)
were from Abcam. The anti-phospho-Histone H3 antibody (06–
570, IF, 1:300) was obtained from Upstate Cell Signaling Solu-
tions. The anti-CCND1 antibody (556470, WB, 1:2500; IHC, 1:300)
was purchased from BD Biosciences. Antibodies for CCND2 (sc-
593, WB, 1:10,000; IHC, 1:20,000) and MLC2V (sc-34490, WB,
1:2500) were from Santa Cruz Biotechnology. Antibodies for
ACTC1 (A9357, WB, 1:5000; IHC 1:3000), ACTA2 (A2547, WB,
1:10,000; IHC 1:3000), and ID2 (HPA027612, WB 1:500; IHC
1:8000) were from Sigma. Antibodies for BrdU (IF, 1:200), TNNT2
(WB, 1:2000; IF 1:200), and b-tubulin (WB, 1:50,000) were
provided by the Developmental Studies Hybridoma Bank at the
University of Iowa. Antibodies for p70S6K (9202, WB, 1:2000; IHC
1:200), ERRB2 (29D8, WB, 1:1000; IF, 1:200), ERRB4 (111B2, WB,
1:1000), mTOR (7C10, WB, 1:1000), and AKT (9272, WB, 1:2000)
were supplied by Cell Signaling. Antibodies for ACTA1 (NBP1-
35265, WB, 1:5000; IHC 1:20,000) and TNNI3 (NBP1-56641, WB,
1:10,000) were from Novus Biologicals. MLC2A antibody (WB,
1:15,000) was a gift from S. Kubalak at the University of South
Carolina. Recombinant human BMP10 and NRG1-b1 were pur-
chased from R&D Systems (377-HB). ERBB2 inhibitor, AG 1478,
was from Calbiochem (658552). DMH1 was from Sigma. Fluor-
escent wheat germ agglutinin (WGA) conjugate Oregon Green
488 (IF, 10 mg/ml) was purchased from Invitrogen.Results
Conditional deletion of Mycn in the developing mouse myocardium
causes embryonic lethality
To investigate the speciﬁc role of myocardial Mycn during
heart development, Mycn was deleted from the myocardium by
crossing male cTnt-Cre;Mycnloxp/wt mice with Mycnloxp/loxp females
(Knoepﬂer et al., 2002). cTnt-Cre efﬁciently deletes target genes
within the cardiomyocyte lineage between embryonic day 9.5
(E9.5) and E10.5 (Chen et al., 2006; Ilagan et al., 2006; Jiao et al.,
2003; Wang et al., 2001, 2000). Deletion of Mycn was conﬁrmed
with PCR analyses on genomic DNA from E10.5 embryos (Fig. 1A
and B). The unrecombined Mycnloxp allele was reduced in cTnt-
Cre;Mycnloxp/loxp mutant hearts to approximately 25% of the
controls (Mycnloxp/loxp). The recombined Mycnloxp allele was
detected only in mutant hearts. MYCN reduction was conﬁrmed
at the protein level with Western blot experiments on proteins
extracted from E10.5 to E11.5 ventricles (Fig. 1C).
Embryos heterozygous for myocardialMycn (cTnt-Cre;Mycnloxp/wt)
developed normally and were viable in adulthood. cTnt-Cre;
Mycnloxp/loxp mutants were recovered at the expected Mendelianfrequency until E12.5, at which point they were no longer isolated
alive (Fig. 1D, Supplementary Table 1). Living embryos were
deﬁned by beating hearts. At E12.5, mutants had delayed devel-
opment and internal hemorrhaging (Fig. 1E). This result strongly
suggests that deletion of Mycn from the myocardium disrupts
mouse cardiogenesis, resulting in embryonic lethality.Myocardial Mycn is necessary for ventricular wall morphogenesis
Only living embryos were used for the following experiments.
To examine cardiac defects, we performed detailed histological
examination of E9.5–E11.5 embryos. Mutants began to display a
thin-walled ventricle phenotype at E9.5, which progressively
became more pronounced until E11.5, the latest stage of survival,
when mutant ventricles were extremely thin and almost com-
pletely devoid of trabeculae (Fig. 2A through F). Atrial myocar-
dium was also noticeably thinner in mutant hearts at E10.5 and
E11.5. Development of the cushions and outﬂow tract appeared to
occur normally. Myocardial wall thickening and trabecular layer
formation are necessary for proper ventricle contractility and
embryo survival. Impaired myocardial wall morphogenesis in
mutant hearts likely caused cardiovascular insufﬁciency, resulting
in embryonic lethality.Expression of MYCN is regulated by both EGF and BMP pathways
The thin myocardium in cTnt-Cre;Mycnloxp/loxp mutant ventri-
cles resembles that of mouse models with disruption of Bmp10
(Chen et al., 2004) and Neuregulin-1 (Nrg-1) (Gassmann et al.,
1995; Lai et al., 2010; Lee et al., 1995; Meyer and Birchmeier,
1995) signaling pathways. Therefore, we directly tested whether
expression of MYCN in embryonic hearts can be regulated by BMP
and EGF pathways. Although BMP10 treatment did not increase
MYCN expression, blocking BMP signaling using a BMP speciﬁc
inhibitor, DMH1 (Hao et al., 2010; Wiley et al., 2011), reduced
expression of MYCN in cultured embryonic hearts (Fig. 3A). This
result suggests that endogenous BMP activity is required for the
normal level of MYCN expression. Our data thus conﬁrmed
previous observations that myocardial Mycn is a transcriptional
target of BMP signaling (Cai et al., 2005; Song et al., 2007b). To
determine if MYCN expression can also be regulated by NRG1
signaling, we treated wild type E11.5 cultured hearts with NRG1-
b1 (Carlsson et al., 2011; Clewes et al., 2011; Safa et al., 2011;
Young et al., 2005) and found that MYCN protein levels were
increased with NRG1-b1 stimulation (Fig. 3A). Furthermore,
application of AG1478, which is a pharmacological inhibitor of
the NRG1 receptor, ERRB2, (Fukazawa et al., 2003; Honjo et al.,
2008; Kim et al., 2007; Rohrbach et al., 2005) to cultured E11.5
hearts reduced expression of MYCN (Fig. 3A). These results
strongly suggest that Mycn expression is maintained in the
myocardium by both BMP and NRG1 signaling pathways.
We further examined whetherMycn can regulate expression of
BMP10 and ERBB2/4. Western analysis using proteins extracted
from mutant and littermate control embryonic hearts (E11.5)
showed that myocardial deletion of Mycn led to reduced expres-
sion of ERBB2 in embryonic hearts and has no effect on expression
of BMP10 or ERBB4 (Fig. 3B). The result observed with Bmp10 is
consistent with the in situ hybridization experiment shown in
Supplementary Fig. 1. Reduced expression of ERBB2 in mutant
hearts was conﬁrmed with an immunoﬂuorescence study (Fig. 3C
and D). Thus, our results suggest a reciprocal regulation between
Mycn and ErbB2 in embryonic hearts.
Fig. 2. Thin myocardial wall defect in cTnt-Cre;Mycnloxp/loxp embryonic hearts. (A)–(F1), Hematoxylin/eosin-stained sagittal sections of embryos from E9.5 ((A)–(B1)), E10.5
((C)–(D1)), and E11.5 ((E)–(F1)). (A1)–(F1) correspond to the boxed regions of (A)–(F), respectively. Open arrows indicate ventricular myocardial wall. Closed arrows point to
trabeculae. Ctrl, Mycnloxp/loxp controls; Cko, cTnt-Cre;Mycnloxp/loxp conditional knockout.
Fig. 1. Conditional deletion of Mycn from the myocardium causes embryonic lethality. (A) PCR analysis was performed on genomic DNA (100 ng) isolated from embryonic
yolk sacs with genotyping primers for cTnt-Cre and the unrecombined Mycnloxp allele. (B) Genomic DNA from control (Mycnloxp/loxp) and mutant (cTnt-Cre;Mycnloxp/loxp)
embryonic hearts was analyzed with semiquantitative PCR using primers for the unrecombined Mycnloxp allele (top). Lanes 1 to 4 are control samples with 100, 50, 25 and
12.5 ng of input DNA. Lane 5 is a mutant sample with 100 ng of input DNA. The unrecombined Mycnloxp allele was reduced in mutant hearts to approximately 25% of the
control. Smad4 primers were used as a loading control (middle). Bottom, heart DNA was analyzed with PCR using primers for the recombined Mycnloxp allele, which was
only detected in mutant hearts. (C) Loss of MYCN in mutant ventricles was conﬁrmed using Western blot analysis on pooled embryonic ventricle protein lysate from
control and mutant embryos. Protein samples were pooled from at least 5 embryos for each experiment. b-tubulin served as the loading control. The band intensity was
semi-quantiﬁed using ImageJ. (D) No living mutants were recovered after E11.5. At least 9 litters were collected at each stage. (E) At E12.5, a dead mutant embryo (left)
was underdeveloped and exhibited hemorrhaging, compared to a littermate control (right). Ctrl, Mycnloxp/loxp controls; Cko, cTnt-Cre;Mycnloxp/loxp conditional knockout.
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Fig. 3. Regulation of MYCN expression by BMP and EGF signaling pathways. (A) Wild type E11.5 embryonic hearts were cultured 2 h with BMP10 (100 ng/ml), BMP
inhibitor DMH1 (8 uM), Neuregulin-1 (625 ng/ml), or ERBB2 inhibitor AG1478 (100 uM). Western analysis was performed using an anti-MYCN antibody. Similar results
were obtained with BMP2- and BMP4-treatment (data not shown). b-tubulin served as the loading control. (B) Total proteins were isolated from E11.5 embryonic hearts
followed by Western analysis using antibodies against BMP10, ERBB2 and ERBB4. Tubulin was used as the loading control. (C)and (D), Immunoﬂuorescence staining was
performed on sagittal sections of E10.5 control and mutant embryos using an anti-ERBB2 antibody (green). Total nuclei were visualized by DAPI staining. Ctrl,Mycnloxp/loxp
controls; Cko, cTnt-Cre;Mycnloxp/loxp conditional knockout.
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contributes to hypocellular myocardial wall in mutant ventricles
MYCN regulates gene expression programs in a tissue-speciﬁc
manner to control cellular processes such as proliferation, survi-
val, growth, and differentiation (Adhikary and Eilers, 2005;
Hurlin, 2005). To determine if loss of myocardial Mycn altered
proliferation, cardiomyocyte number and proliferation rate were
measured. A signiﬁcant reduction in cardiomyocyte number was
found in mutant ventricles at E9.5 (P¼0.001, Fig. 4A). Cardio-
myocyte proliferation was measured using immunoﬂuorescence
assays with an antibody for pH3, a marker for mitotic cells.
Mutants had signiﬁcantly reduced cardiomyocyte proliferation
in the ventricles (P¼0.02, Fig. 4B through D). Reduced cell
proliferation in mutant ventricles was further conﬁrmed with a
BrdU labeling experiment (Supplementary Fig. 2).
To test if Mycn was necessary for cardiomyocyte survival
during cardiogenesis, apoptosis was measured using TUNEL
assays. No changes in apoptosis were detected in the mutant
hearts from E9.5 to E11.5 (Supplemental Fig. 3). Therefore,
decreased cardiomyocyte proliferation, but not increased apop-
tosis, contributed to the hypocellular myocardial wall phenotype
in mutant ventricles.
Mycn is required for expression of cell cycle regulators CCND1,
CCND2, and ID2 in the ventricular myocardium
MYC proteins are important activators of proliferation through
their ability to upregulate cell cycle regulatory genes (Adhikary
and Eilers, 2005; Hurlin, 2005). To better understand the mechan-
ism whereby MYCN regulates cardiomyocyte proliferation during
heart development, we measured the levels of MYCN targets
cyclin D1 (CCND1) (Kenney et al., 2003), cyclin D2 (CCND2)
(Bouchard et al., 2001, 1999), and inhibitor of DNA binding 2
(ID2) (Lasorella et al., 2002, 2000). Proteins were extracted from
embryonic ventricles and analyzed with Western blot experi-
ments. All three proteins were signiﬁcantly decreased in mutant
ventricles from E10.5 to E11.5 (Po0.001, Fig. 5A). These results
were conﬁrmed with immunohistochemistry experiments(Fig. 5B through G). These data indicate that MYCN promotes
cardiomyocyte proliferation at least in part through upregulation
of CCND1, CCND2, and ID2.
Mutant hearts have smaller cardiomyocytes and decreased levels of
p70S6K, a regulator of cell growth
Through its regulation of the cell cycle, ribosome synthesis,
and protein translation, MYCN ultimately enhances cell size
(Adhikary and Eilers, 2005; Hurlin, 2005). To investigate if Mycn
was required for cardiomyocyte growth, we measured cardio-
myocyte width in cryosections of control and mutant ventricle
walls at E10.5. Membranes of cardiomyocytes were labeled with
anti-WGA (Condorelli et al., 2002) (green, Fig. 6A–B1) and cell
width was measured as described in (Wang et al., 2010). The size
of cardiomyocytes was signiﬁcantly reduced in mutant hearts
(Po0.001, Student’s t test) as shown in Fig. 6C. Similar results
were observed on parafﬁn sections (data not shown).
To further elucidate how MYCN promotes cardiomyocyte
growth, we examined expression of ribosomal protein S6 kinase I
(p70S6K), a well-known regulator of ribosome biogenesis and cell
growth (Ahuja et al., 2007; Crackower et al., 2002; Fingar et al.,
2002; Shima et al., 1998; Shioi et al., 2000). Western blot experi-
ments on E10.5–E11.5 ventricle proteins revealed that mutants had
a noticeable reduction of p70S6K (Fig. 7A). Expression of p70S6K
upstream genes, including Akt and mTOR, was not altered by
deletion of Mycn (Fig. 7A). Decreased expression of p70S6K was
conﬁrmed with immunohistochemistry assays in E10.5 ventricular
myocardium (Fig. 7B–C1). These data suggest that p70S6K is a
regulatory target of MYCN in controlling cardiomyocyte size.
Aberrant cardiac myoﬁlament gene expression in Mycn-depleted
ventricles
During development, MYCN is necessary for maintaining
certain cell types in a proliferative, undifferentiated state
(Knoepﬂer et al., 2002; Okubo et al., 2005). To determine if
Mycn-depletion causes premature cardiomyocyte differentiation,
we examined myoﬁlament proteins including myosin heavy chain
Fig. 4. Cell number and proliferation analysis of E9.5 embryonic hearts. (A),
Sagittal sections of E9.5 embryos were analyzed with DAPI staining to identify
nuclei. Total nuclei were counted within 4 regions of the heart: the atrial
myocardium, AVC myocardium, cushion mesenchyme, and ventricular myocar-
dium. Three embryos were analyzed from three different litters, and at least three
sections were analyzed for each embryo. Mutant ventricles displayed a signiﬁcant
decrease in cardiomyocyte number (Student’s t test, p¼0.001). SEMs for control
measurements were: Atria þ/9.1, AVC þ/3, Cushion þ/3.4, and Ventricle
þ/18.9. Mutant SEMs were: Atria þ/8.2, AVC þ/4.4, Cushion þ/5.8, and
Ventricle þ/19.2. (B) Cell proliferation experiments were performed on sagittal
sections of E9.5 embryos using antibodies against phospho-Histone H3 (pH3) to
mark mitotic cells and DAPI to identify nuclei. Cells were counted within 4 regions
of the heart: the atrial myocardium, AVC myocardium, cushion mesenchyme, and
ventricular myocardium. Proliferation was calculated as total pH3-positive nuclei
divided by total nuclei; the result was expressed as the mean percentage of pH3-
positive cells/total number of nuclei. Three embryos were analyzed from three
different litters, and at least three sections were analyzed for each embryo. A
signiﬁcant decrease in cardiomyocyte proliferation was evident in mutant ven-
tricles (Student’s t test, Po0.02). Error bars represent standard deviation. (C)–(D)
Representative images from pH3 immunostaining experiments on sagittal sec-
tions of E9.5 control ((C)–(C1)) and mutant (D)–(D1)) embryos. (C1) and (D1)
correspond to boxed regions of (C) and (D), respectively. Arrows point to examples
of cardiomyocytes positive for pH3 (green). Total nuclei were stained with DAPI
(blue). Ctrl, Mycnloxp/loxp controls; Cko, cTnt-Cre;Mycnloxp/loxp conditional knockout;
A, atria; AVC, atrioventricular canal; Cush, endocardial cushion; V or Vent,
ventricle.
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patterns in embryonic, less differentiated cardiomyocytes versus
adult, differentiated cardiomyocytes (Fig. 8A). For myosin heavy
chain proteins, expression of the embryonic form, b-MHC
(Morkin, 2000), was not changed, while expression of the adult
form, a-MHC (Morkin, 2000), was reduced. For actins, no differ-
ence was observed in either embryonic forms [a-skeletal actin (a-
ACTA1) (Cle´ment et al., 2007) and a-smooth muscle actin (a-
ACTA2) (Cle´ment et al., 2007)] or the adult form [a-cardiac actin
(a-ACTC1) (Cle´ment et al., 2007)]. For troponin I, expression of the
adult form [TNNI3 (Bhavsar et al., 1991; Hunkeler et al., 1991)]
was increased while that of the embryonic form (TNNI2)
was decreased in mutant hearts. We next analyzed the expression
of a group of myoﬁlament proteins necessary for propercardiomyocyte structure and function. Western blot experiments
showed that E11.0 mutant ventricles had reduced expression of
myosin light chain 1V (MLC1V), MLC2V, and MLC2A. Expression
of troponin T2 was not altered in mutant hearts. Our data suggest
that Mycn is required for normal expression of multiple myoﬁla-
ment proteins. Abnormal expression of cardiac structural proteins
may contribute to the myocardial wall defects in mutant hearts.Discussion
The major goal of this study was to reveal the precise
cardiogenic functions of Mycn. Haploinsufﬁciency for MYCN
causes Feingold syndrome, which is characterized in part by
CHDs (Brunner and Winter, 1991; Bu¨ttiker et al., 2000; Celli
et al., 2003; Genevieve et al., 2007; Piersall et al., 2000; van
Bokhoven et al., 2005). Previous reports have shown that global
loss of MYCN (Charron et al., 1992; Sawai et al., 1993; Stanton
et al., 1992) or severe reduction in MYCN (Moens et al., 1993)
during mouse embryogenesis causes varying and complex CHDs.
We show for the ﬁrst time that depletion of Mycn solely in the
developing myocardium leads to abnormal myocardial wall
morphogenesis and embryonic lethality at midgestation. Our
study thus deﬁnitively establishes that the developing myocar-
dium requires MYCN and supports the notion that impaired
activity of Mycn in the myocardium may contribute directly to
the heart defects observed in Feingold syndrome patients.
Myocardial inactivation of Mycn led to embryonic lethality at
E12.5, roughly the same time as global knockout mouse models
(Charron et al., 1992; Sawai et al., 1993; Stanton et al., 1992) and
earlier than in the hypomorphic mice (Moens et al., 1993). This
result strongly suggests that defective cardiogenesis due to loss of
Mycn within the myocardium was the primary cause of lethality in
earlier models. In the present study, the mutant phenotype was
restricted to the myocardial wall. Other aspects of cardiac morpho-
genesis such as AVC cushion development and IVS initiation
occurred normally, indicating that myocardialMycn is not necessary
for those aspects of cardiogenesis. Interestingly, Mycn-null mice
displayed abnormal valvuloseptal development (Charron et al.,
1992). We speculate that endocardial, but not myocardial, Mycn is
required for proper cushion morphogenesis. This idea is substan-
tiated by a recent report showing that Mycn is a downstream target
of BMP2-induced TBX20 regulation in chicken endocardial cushion
culture systems (Shelton and Yutzey, 2007).
BMP10 (Chen et al., 2004; Grego-Bessa et al., 2007; Zhang
et al., 2011) and NRG1 (Gassmann et al., 1995; Lai et al., 2010; Lee
et al., 1995; Meyer and Birchmeier, 1995) are central regulators
for myocardial wall development. Myocardial inactivation of
Mycn resulted in the thin-walled defect similar to that observed
in embryos with deletion of Bmp10 (Chen et al., 2004), Nrg1 (Lai
et al., 2010), and ErbB2/4 (Gassmann et al., 1995; Lee et al., 1995;
Meyer and Birchmeier, 1995). Previous studies suggested that
Mycn is a transcriptional target of BMP signaling during heart
development (Cai et al., 2005; Song et al., 2007b). We conﬁrmed
this by showing that blocking endogenous BMP signaling using a
BMP speciﬁc inhibitor reduced expression of MYCN in cultured
embryonic hearts (Fig. 3). Expression of cell cycle regulators
including CCND1, 2 and ID2 (Fig. 5) was reduced in Mycn knock-
out embryonic hearts, a deﬁciency which was also observed in
Smad4 myocardial inactivation mice (Song et al., 2007b). Our
study thus provides further support for the hypothesis that MYCN
acts as a critical mediator of BMP signaling during cardiogenesis.
We show for the ﬁrst time that exogenous NRG1 can sufﬁciently
upregulate MYCN expression and that blocking its receptor (ERRB2)
can downregulate MYCN expression in cultured embryonic hearts
(Fig. 3). The potential role of EGF signaling in regulating Mycn
Fig. 5. Examination of MYCN targets CCND1, CCND2, and ID2. (A) Western blot experiments with proteins extracted from E10.5 to E11.5 control and mutant ventricles
revealed decreased expression of cell cycle regulators. b-tubulin served as the loading control. Ventricle protein samples were pooled from at least 5 embryos for each
experiment and each experiment was repeated at least 3 times. Quantiﬁcation of Western blot results using ImageJ showed a signiﬁcant decrease in all three proteins
(Student’s t test, Po0.001). (B)–(G), Immunohistochemistry for CCND1, CCND2 and ID2 on E10.5 control ((B), (D), (F)) and mutant ((C), (E), (G)) ventricles. The overall
staining intensity was reduced in mutant ventricle myocardium. In addition, the number of strongly stained cells was also reduced in mutants. Red arrowheads point to
examples of strongly stained cardiomyocytes. Ctrl, Mycnloxp/loxp controls; Cko, cTnt-Cre;Mycnloxp/loxp conditional knockout.
C. Harmelink et al. / Developmental Biology 373 (2013) 53–63 59expression has not been well documented in the literature. It was
recently reported that EGF stimulation can recruit Sp1 to the MYCN
promoter to activate its expression in neuroblastoma-derived cell
lines (Hossain et al., 2012). We are currently investigating whether
NRG1 can regulateMycn transcription through a similar mechanism
in developing hearts. Our study revealed further that ErbB2 is anovel target (direct or indirect) of MYCN in embryonic hearts,
suggesting a positive feedback loop between NRG1 signaling and
MYCN in developing ventricles. The mutually positive regulation
between NRG1 signaling and MYCN can reinforce both their
activities to ensure proper proliferation/differentiation of cardio-
myocytes. Collectively, our data suggest that MYCN acts as a hub for
Fig. 6. Measurement of cardiomyocyte size. (A)–(B), Representative cryosections of embryonic ventricle myocardium from control ((A)–(A1)) and mutant ((B)–(B1)) hearts
at E10.5. Cell membranes were labeled by WGA (green), cardiomyocytes were labeled with anti-TNNT2 (red), and nuclei were labeled with DAPI (blue). (C) Measurements
of cardiomyocyte width were made from comparable regions of mutant and control ventricles at E10.5. Mutant cardiomyocytes were signiﬁcantly smaller than controls.
Cardiomyocyte width was measured as the shortest axis through the middle of the nucleus, as described in Wang et al. (2010). Three embryos were analyzed from
2 different litters, and at least 3 sections were analyzed for each embryo. Error bars represent standard error. #: Student’s t test, Po0.001. Scale bar: 20 um.
Fig. 7. Reduced expression of p70S6K in mutant myocardium. (A) Western blot
assays were performed on proteins extracted from E10.5 to E11.5 embryonic heart
ventricles using antibodies as indicated. Protein samples were pooled from at least
5 embryonic ventricles. b-tubulin served as the loading control. (B)–(C), Loss of
p70S6K in mutant ventricles was conﬁrmed with immunohistochemistry on E10.5
control ((B)–(B1)) and mutant ((C)–(C1)) ventricles. (B1) and (C1) correspond to the
boxed regions of (B) and (C), respectively. Arrows point to examples of cardio-
myocytes without p70S6K. Ctrl, Mycnloxp/loxp controls; Cko, cTnt-Cre;Mycnloxp/loxp
conditional knockout; V, ventricle.
C. Harmelink et al. / Developmental Biology 373 (2013) 53–6360mediating both BMP and NRG1 signaling pathways to promote
normal myocardial wall morphogenesis. It will be interesting in
future studies to determine whether overexpression of Mycn in
hearts can rescue the cardiac wall defects caused by disruption of
Bmp10 and/or Nrg1/ErbB2,4.
Cell proliferation and growth are tightly coupled during develop-
ment (Ahuja et al., 2007) and yet how this is achieved in embryonic
cardiomyocytes is not well understood. Since MYC proteins can
promote cell growth (Adhikary and Eilers, 2005; Hurlin, 2005) wewanted to determine if loss ofMycn stunted cardiomyocyte growth in
addition to reducing proliferation. Indeed, loss of myocardial Mycn
caused a signiﬁcant size reduction in ventricular cardiomyocytes
(Fig. 6). This result is consistent with a previous study showing that
ectopic expression of c-Myc led to hypertrophy in adult hearts (Xiao
et al., 2001). The dual roles of Mycn provide a potential molecular
mechanism for the coordinated regulation of cell proliferation and
growth during heart development.
We further showed that MYCN mediates cardiomyocyte growth
(at least in part) by maintaining proper expression of p70S6K within
the ventricles (Fig. 7). p70S6K acts downstream of the Akt/mTOR
pathway and is a well-known regulator of cell growth during
development and in adult diseases such as cardiac hypertrophy
(Ahuja et al., 2007; Crackower et al., 2002; Fingar et al., 2002;
Pereira et al., 2009; Shima et al., 1998; Shioi et al., 2000; Takano
et al., 1996). Recent studies have implicated that the Akt/mTOR/
p70S6K pathway and MYC act coordinately in different cellular
events including cell proliferation and metabolism (Schramm et al.,
2012; Wang et al., 2012; Ward and Thompson, 2012). Our results
show that MYC can regulate expression of p70S6K and thus provide
clues as to how exactly MYC interacts with the Akt/mTOR/p70S6K
pathway. We are currently testing whether p70S6K is a direct target
of MYCN. It is noteworthy that both MYC and p70S6K have been
known to regulate cardiac hypertrophy and may serve as potential
therapeutic targets for cardiomyopathy (Boluyt et al., 2004; Hurlin,
2005; Kang et al., 2011; Olson et al., 2012;Wolfram et al., 2011). Our
ﬁndings from embryonic hearts may also inform how their activities
are regulated in postnatal hypertrophic cardiomyopathy.
MYCN has been described as a ‘‘molecular switch’’ (Charron
et al., 1992) that serves to keep cells in a proliferative, undiffer-
entiated state since Mycn is expressed in proliferative, undiffer-
entiated cell populations (Kato et al., 1991) and conditional
deletion of Mycn has been reported to alter differentiation of
various cell types (Knoepﬂer et al., 2002; Okubo et al., 2005; Ota
et al., 2007). We investigated the possibility that loss of myocar-
dial Mycn in mutant ventricles altered normal cardiac structural
gene expression patterns. Among the group of proteins that are
differentially expressed in embryonic hearts vs. adult hearts, only
Fig. 8. Analysis of structural protein expression. (A), Expression of myoﬁlament proteins was examined by Western blot analysis on protein extracts from E11.0 heart
ventricles using antibodies as indicated. b-tubulin served as the loading control. Ventricle proteins were extracted and pooled from at least 5 embryos. (B) Altered
expression of a-MHC, MLC1V, MLC2V, MLC2A, TNNI2, TNNI3 was semi-quantiﬁed using ImageJ. Data were averaged from three independent experiments. Black bars
represent the level of control hearts, while the white bars represent that of mutant hearts. Error bars represent standard deviation. Ctrl,Mycnloxp/loxp controls; Cko, cTnt-Cre;
Mycnloxp/loxp conditional knockout; V, ventricle; *: Po0.05 (Student’s t test); #: P¼0.07o0.1.
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embryonic form (TNNI2) to the adult form (TNNI3) (Fig. 8). Such
a premature shift was not observed in myosin heavy chain
proteins (a-MHC, b-MHC) or actins (a-ACTA1, a-ACTA2, a-
ACTC1). Therefore, our results do not support that embryonic
cardiomyocytes lacking MYCN undergo general prematuration.
Despite their high structural similarities, TNNI2 and TNNI3 show
different activities in regulating contraction of cardiac myoﬁbrils
(Fentzke et al., 1999; Westfall and Metzger, 2001; Westfall et al.,
2001). Compared to cardiac myoﬁlaments associated with TNNI3,
those associated with TNNI2 display a higher Ca2þ sensitivity of
tension and do not respond to cAMP-dependent protein kinase
(PKA) (ibid.). Proper switching of TNNI forms during cardiomyo-
cyte maturation is essential for normal activities of cardiac
myoﬁlaments. Ectopic myocardial expression of TNNI2 in a
transgenic model or a delay in switching off TNNI2 in mXinb
knockout mice led to diastolic dysfunction (Fentzke et al., 1999;
Wang et al., 2010). Thus, the premature switch of TNNI proteins
may impair Ca2þ sensitivity of cardiac myoﬁbrils and have a
negative effect on cardiomyocyte relaxation/contraction in
mutant hearts.
In addition to TNNI proteins, we observed reduced expression
of a-MHC, MLC1V, MLC2A, and MLC2V in mutant ventricles. We
conclude that Mycn is required for normal cardiomyocyte differ-
entiation by maintaining expression of multiple sarcomere pro-
teins during ventricular myocardial wall morphogenesis. It is
unclear at present whether these genes are direct downstream
targets of MYCN. We cannot fully exclude that abnormal expres-
sion of sarcomere proteins is secondary to proliferation and/or
trabeculation defects in mutants. However, we feel that this is
unlikely as such a phenotype has not been reported in some other
mouse models with a similar thin-walled abnormality. For exam-
ple, reduced expression of MLC2V and MLC2A occurred in Nrg1
knockout hearts (Lai et al., 2010) but not in hearts lacking Bmp10
(Chen et al., 2004).
In summary, deletion of myocardial Mycn resulted in hypo-
plastic ventricle walls with dramatically reduced trabeculation.
These cardiac defects cause embryonic lethality at midgestation.Mycn is necessary for myocardial wall morphogenesis through its
regulation of cardiomyocyte proliferation, growth, cardiac struc-
tural gene expression, and differentiation.Funding
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